BioLexis Pte Ltd. 13D and 13G filings for Outlook Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-01-31 4:01 pm Sale | 2024-01-25 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 831,851 6.400% | -135,723 (-14.03%) | Filing |
| 2023-11-29 4:01 pm Sale | 2023-11-10 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 967,575 7.400% | -181,552 (-15.80%) | Filing |
| 2022-07-07 9:51 pm Sale | 2022-07-05 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 1,149,126 10.200% | -1,703,229 (-59.71%) | Filing |
| 2022-04-22 4:30 pm Sale | 2022-04-21 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 2,852,355 25.600% | -1,149,126 (-28.72%) | Filing |
| 2022-02-01 4:58 pm Unchanged | 2022-02-01 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 4,001,482 35.700% | 0 (Unchanged) | Filing |
| 2021-12-01 5:27 pm Purchase | 2021-11-29 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 4,001,482 35.500% | 850,681 (+27.00%) | Filing |
| 2021-02-02 5:27 pm Purchase | 2021-02-02 | 13D | Outlook Therapeutics, Inc. OTLK | BioLexis Pte Ltd. | 3,150,800 38.600% | 418,000 (+15.30%) | Filing |